Document is current
Any future updates will be listed below
-
Authors
Shiba-Ishii, Aya
Johnson, Ted W.
Dagogo-Jack, Ibiayi
Mino-Kenudson, Mari https://orcid.org/0000-0002-9092-2265
Johnson, Theodore R.
Wei, Ping
Weinrich, Scott L.
McTigue, Michele A.
Walcott, Makeba A.
Nguyen-Phuong, Linh
Dionne, Kristin
Acker, Adam
Kiedrowski, Lesli A. https://orcid.org/0000-0001-5081-2005
Do, Andrew
Peterson, Jennifer L.
Barth, Jaimie L.
Yeap, Beow Y.
Gainor, Justin F. https://orcid.org/0000-0001-8697-4081
Lin, Jessica J. https://orcid.org/0000-0001-7373-3916
Yoda, Satoshi https://orcid.org/0000-0003-4201-1392
Hata, Aaron N. https://orcid.org/0000-0002-6127-318X
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K12CA087723–16, R01CA164273)
Lung Cancer Research Foundation
Be a Piece of the Solution Targeting a Cure for Lung Cancer Research Fund
- License Information
-
More Information
Article History
Received: 29 June 2021
Accepted: 18 May 2022
First Online: 20 June 2022
Competing interests
: T.W.J., T.R.J., P.W., S.L.W. and M.A.M. are employees of Pfizer. I.D.J. has received honoraria from Foundation Medicine, Creative Education Concepts and American Lung Association, consulting fees from Guidepost, AstraZeneca, Boehringer Ingelheim, BostonGene, Catalyst, Novocure, Pfizer, Syros and Xcovery, research support from Array, Genentech, Novartis, Pfizer and Guardant Health and travel support from Array and Pfizer. L.A.K. is an employee and shareholder of Guardant Health. J.F.G. has served as a compensated consultant or received honoraria from Bristol-Myers Squibb, Genentech, Ariad/Takeda, Loxo, Pfizer, Incyte, Novartis, Merck, Agios, Amgen, Jounce, Karyopharm, GlydeBio, Regeneron, Oncorus, Helsinn, Jounce, Array and Clovis Oncology, has an immediate family member who is an employee with equity in Ironwood Pharmaceuticals, has received research funding from Novartis, Genentech/Roche and Ariad/Takeda and institutional research support from Tesaro, Moderna, Blueprint, BMS, Jounce, Array, Adaptimmune, Novartis, Genentech/Roche, Alexo and Merck. J.J.L. has served as a compensated consultant for Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Turning Point Therapeutics, Mirati Therapeutics, Bayer and Elevation Oncology; received honorarium and travel support from Pfizer; received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche/Genentech, Pfizer, Nuvalent, Linnaeus Therapeutics and Novartis; received continuing medical education funding from OncLive, MedStar Health and Northwell Health. S.Y. is an employee of Tango Therapeutics and has received a consulting fee from Pfizer Japan and Nuvalent. A.N.H. has received research support from Pfizer, Nuvalent, Roche/Genentech, Amgen, Blueprint Medicines, Eli Lilly, Scorpion Therapeutics, Bristol-Myers Squibb, BridgeBio and Relay Therapeutics; has served as a compensated consultant for Nuvalent, Tolremo Therapeutics, Engine Biosciences and TigaTx. The remaining authors declare no competing interests.
